Insider · CIK 0001599214
Chen Bihua
Reports to the SEC for 42 companies · BOSTON, MA
Transactions
50
Companies
42
Filings
6
CIK
0001599214
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-08-10 | BLSMBlossomHill Therapeutics, Inc.C Conversion | — |
| 2026-08-10 | BLSMBlossomHill Therapeutics, Inc. · Series A Preferred StockC Conversion | — |
| 2026-08-10 | BLSMBlossomHill Therapeutics, Inc. · Series B Preferred StockC Conversion | — |
| 2026-08-10 | BLSMBlossomHill Therapeutics, Inc.P Purchase | +$5M |
| 2026-08-10 | BLSMBlossomHill Therapeutics, Inc.C Conversion | — |
| 2026-08-06 | BLSMBlossomHill Therapeutics, Inc. · Director Stock Option (Right to Buy)A Award | — |
| 2026-07-01 | BBOTBridgeBio Oncology Therapeutics, Inc.J Other | — |
| 2026-07-01 | BBOTBridgeBio Oncology Therapeutics, Inc.J Other | — |
| 2026-07-01 | BBOTBridgeBio Oncology Therapeutics, Inc.J Other | — |
| 2026-07-01 | BBOTBridgeBio Oncology Therapeutics, Inc.J Other | — |
| 2026-06-16 | BBOTBridgeBio Oncology Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2026-01-26 | HLXCHelix Acquisition Corp. IIIA Award | +$4.98M |
| 2026-01-26 | HLXCHelix Acquisition Corp. IIIA Award | +$4.98M |
| 2026-01-26 | HLXCHelix Acquisition Corp. IIIP Purchase | +$8M |
| 2026-01-22 | HLXCHelix Acquisition Corp. III · Class B Ordinary SharesJ Other | — |
| 2026-01-22 | HLXCHelix Acquisition Corp. III · Class B Ordinary SharesJ Other | — |
| 2025-09-30 | MLTXMoonLake ImmunotherapeuticsS Sale | −$40.6K |
| 2025-09-29 | MLTXMoonLake ImmunotherapeuticsS Sale | −$1.95M |
| 2025-09-29 | MLTXMoonLake ImmunotherapeuticsS Sale | −$25.7M |
| 2025-09-29 | MLTXMoonLake ImmunotherapeuticsS Sale | −$18.5M |
| 2025-09-29 | MLTXMoonLake ImmunotherapeuticsS Sale | −$664K |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.M Exercise/Conversion | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.D Disposition to Issuer | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | +$8.15M |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | +$6.85M |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | +$60M |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc. · Class B ordinary sharesD Disposition to Issuer | — |
| 2025-08-11 | BBOTBridgeBio Oncology Therapeutics, Inc. · Class B ordinary sharesM Exercise/Conversion | — |
| 2025-06-11 | BMEABiomea Fusion, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-02-08 | BBOTBridgeBio Oncology Therapeutics, Inc. · Class B Ordinary SharesJ Other | — |
| 2024-06-12 | BMEABiomea Fusion, Inc. · Stock Option (right to buy)A Award | — |
| 2024-02-13 | BBOTBridgeBio Oncology Therapeutics, Inc.P Purchase | +$14.3M |
| 2024-02-13 | BBOTBridgeBio Oncology Therapeutics, Inc.P Purchase | +$9.04M |
| 2024-02-13 | BBOTBridgeBio Oncology Therapeutics, Inc.P Purchase | +$694K |
| 2024-02-13 | BBOTBridgeBio Oncology Therapeutics, Inc.A Award | +$5.09M |
| 2023-10-05 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$3.52M |
| 2023-10-04 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$3.89M |
| 2023-10-03 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$8.62M |
| 2023-10-02 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$4.3M |
| 2023-06-30 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$40M |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$1,059.3 |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$108K |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$17K |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$76.8K |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$25.1K |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$8,459.2 |
| 2023-06-26 | MLTXMoonLake ImmunotherapeuticsP Purchase | +$8,875.15 |
Recent filings
- 4Cormorant Asset Management, LP0001231919-26-000852SEC(opens sec.gov)
- 4Chen Bihua0001213900-26-075538SEC(opens sec.gov)
- 4Chen Bihua0001193125-26-276041SEC(opens sec.gov)
- 4/AChen Bihua0001213900-26-009021SEC(opens sec.gov)
- 4Chen Bihua0001213900-26-007772SEC(opens sec.gov)
- 4Cormorant Asset Management, LP0000929638-25-003712SEC(opens sec.gov)
Companies
- Aardvark Therapeutics, Inc.Former 10% OwnerAARD
- Akouos, Inc.Director, 10% Owner
- Ambrx Biopharma Cayman, Inc.10% Owner
- Ambrx Biopharma, Inc.10% Owner
- Apellis Pharmaceuticals, Inc.Director, 10% OwnerAPLS
- Atea Pharmaceuticals, Inc.Director, 10% OwnerAVIR
- Avidity Biosciences, Inc.Director, 10% OwnerRNAM
- Axonics, Inc.Director, 10% Owner
- BioAge Labs, Inc.Former 10% OwnerBIOA
- BioAtla, Inc.Director, 10% OwnerBCAB
- Biomea Fusion, Inc.Former DirectorBMEA
- BlossomHill Therapeutics, Inc.Director, 10% OwnerBLSM
- BridgeBio Oncology Therapeutics, Inc.Director, 10% OwnerBBOT
- BRIGHT MINDS BIOSCIENCES INC.Former 10% OwnerDRUG
- Cellectar Biosciences, Inc.Director, 10% OwnerCLRB
- Clearside Biomedical, Inc.Director, 10% OwnerCLSDQ
- CONSTELLATION PHARMACEUTICALS INCDirector, 10% Owner
- Corbus Pharmaceuticals Holdings, Inc.10% OwnerCRBP
- Design Therapeutics, Inc.Director, Former 10% OwnerDSGN
- Elevation Oncology, Inc.10% Owner
- Erasca, Inc.DirectorERAS
- EyePoint, Inc.Former 10% OwnerEYPT
- GreenLight Biosciences Holdings, PBC(See below)
- Helix Acquisition Corp. IIIDirector, Chairperson and CEO, 10% OwnerHLXC
- Icosavax, Inc.Former 10% Owner
- Immuneering Corp10% OwnerIMRX
- Jade Biosciences, Inc.Former 10% OwnerJBIO
- Kezar Life Sciences, Inc.Director, 10% OwnerKZR
- KINETA, INC./DEDirector, 10% Owner
- Kiniksa Pharmaceuticals International, plcDirector, 10% OwnerKNSA
- Monte Rosa Therapeutics, Inc.10% OwnerGLUE
- MoonLake ImmunotherapeuticsFormer 10% OwnerMLTX
- Olema Pharmaceuticals, Inc.Director, 10% OwnerOLMA
- OnKure Therapeutics, Inc.Former 10% OwnerOKUR
- Prometheus Biosciences, Inc.Director, Former 10% Owner
- Pyxis Oncology, Inc.Director, Former 10% OwnerPYXS
- Rain Oncology Inc.Director
- Turning Point Therapeutics, Inc.Director, 10% Owner
- Tyra Biosciences, Inc.Director, Former 10% OwnerTYRA
- Ventyx Biosciences, Inc.Former 10% OwnerVTYX
- Verve Therapeutics, Inc.Director
- Vigil Neuroscience, Inc.Former 10% Owner
Address
C/O CORMORANT ASSET MANAGEMENT LP 200 CLARENDON STREET, 50TH FLOOR
BOSTON, MA, 02116